GlassScriptPhysician profile
Leonid Vydro
NPI 1902148380
$7,071.24
in general payments reported to CMS, 2019-2025
44 companies · $575 in 2025
The $575 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,001 · 2020: $1,281 · 2021: $1,461 · 2022: $907 · 2023: $1,038 · 2024: $809 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,421.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,852.65 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,113.88 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Amgen INC. | $647.56 | 2019-2025 | Tepezza, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $530.05 | 2020-2025 | |
| Dexcom, INC. | $286.99 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.50 | 2020-2024 | Jardiance |
| Insulet Corporation | $184.34 | 2019-2024 | Omnipod |
| Medtronic Minimed, INC. | $183.60 | 2019-2020 | |
| Abbott Laboratories | $172.35 | 2020-2024 | Freestyle Libre |
| Sanofi-Aventis U.S. LLC | $167.36 | 2020-2024 | |
| Amneal Pharmaceuticals LLC | $163.90 | 2020-2024 | Unithroid |
| Recordati_rare_diseases_inc. | $124.44 | 2025 | Isturisa |
| Tandem Diabetes Care, INC. | $108.72 | 2020-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $104.32 | 2020-2024 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $93.96 | 2022-2024 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Vydro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.